INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,338 | -38.4% | 3,439 | -29.3% | 0.00% | – |
| Q2 2023 | $2,171 | -99.9% | 4,862 | -99.7% | 0.00% | -100.0% |
| Q1 2023 | $1,525,191 | -17.1% | 1,859,989 | +57.6% | 0.00% | 0.0% |
| Q4 2022 | $1,840,847 | -47.0% | 1,180,030 | -41.4% | 0.00% | -50.0% |
| Q3 2022 | $3,475,000 | +30.4% | 2,014,299 | +30.8% | 0.00% | 0.0% |
| Q2 2022 | $2,664,000 | +134.3% | 1,539,843 | +386.5% | 0.00% | +100.0% |
| Q1 2022 | $1,137,000 | -70.3% | 316,492 | -58.7% | 0.00% | -50.0% |
| Q4 2021 | $3,826,000 | +43.5% | 766,725 | +105.9% | 0.00% | 0.0% |
| Q3 2021 | $2,666,000 | -53.6% | 372,318 | -39.9% | 0.00% | -33.3% |
| Q2 2021 | $5,746,000 | +23.4% | 619,848 | +23.5% | 0.00% | 0.0% |
| Q1 2021 | $4,657,000 | +72.5% | 501,857 | +64.5% | 0.00% | +50.0% |
| Q4 2020 | $2,700,000 | -35.1% | 305,080 | -15.0% | 0.00% | -33.3% |
| Q3 2020 | $4,162,000 | -65.8% | 358,806 | -20.5% | 0.00% | -70.0% |
| Q2 2020 | $12,163,000 | +506.9% | 451,315 | +67.6% | 0.01% | +400.0% |
| Q1 2020 | $2,004,000 | +528.2% | 269,349 | +178.4% | 0.00% | – |
| Q4 2019 | $319,000 | +138.1% | 96,746 | +48.7% | 0.00% | – |
| Q3 2019 | $134,000 | -52.3% | 65,063 | -32.1% | 0.00% | – |
| Q2 2019 | $281,000 | -7.9% | 95,756 | +17.1% | 0.00% | – |
| Q1 2019 | $305,000 | -73.6% | 81,772 | -71.7% | 0.00% | -100.0% |
| Q4 2018 | $1,156,000 | -10.6% | 288,993 | +24.2% | 0.00% | 0.0% |
| Q3 2018 | $1,293,000 | +75.0% | 232,615 | +23.2% | 0.00% | 0.0% |
| Q2 2018 | $739,000 | -25.1% | 188,875 | -9.8% | 0.00% | 0.0% |
| Q1 2018 | $986,000 | -3.2% | 209,420 | -15.1% | 0.00% | 0.0% |
| Q4 2017 | $1,019,000 | -12.2% | 246,661 | +34.9% | 0.00% | 0.0% |
| Q3 2017 | $1,160,000 | +39.4% | 182,822 | +72.4% | 0.00% | – |
| Q2 2017 | $832,000 | +83.7% | 106,075 | +55.1% | 0.00% | – |
| Q1 2017 | $453,000 | -67.2% | 68,375 | -65.6% | 0.00% | -100.0% |
| Q4 2016 | $1,380,000 | +51.8% | 198,782 | +103.8% | 0.00% | 0.0% |
| Q3 2016 | $909,000 | +15.9% | 97,534 | +14.9% | 0.00% | 0.0% |
| Q2 2016 | $784,000 | -22.6% | 84,893 | -27.1% | 0.00% | 0.0% |
| Q1 2016 | $1,013,000 | +150.1% | 116,413 | +93.5% | 0.00% | – |
| Q4 2015 | $405,000 | -45.3% | 60,172 | -53.0% | 0.00% | -100.0% |
| Q3 2015 | $740,000 | +45.1% | 127,999 | +104.6% | 0.00% | – |
| Q2 2015 | $510,000 | -4.9% | 62,553 | -4.9% | 0.00% | -100.0% |
| Q1 2015 | $536,000 | -22.4% | 65,752 | -12.8% | 0.00% | 0.0% |
| Q4 2014 | $691,000 | +9.3% | 75,363 | +17.4% | 0.00% | 0.0% |
| Q3 2014 | $632,000 | +11.3% | 64,203 | +22.2% | 0.00% | 0.0% |
| Q2 2014 | $568,000 | – | 52,524 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |